Pharma approval
New diagnosis pathway has been launched to mark European Myeloma Day
The Myeloma Diagnosis Pathway aims to improve early diagnosis for patients
FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions
Inspection of third-party manufacturing plant delayed due to COVID-19
Bristol-Myers Squibb’s revenues rise on Celgene acquisition
Sales of immunotherapy Opdivo decreased due to COVID-19 impact
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma
First cancer drug wholly owned by company to be approved in past decade
Celgene’s Revlimid scores NICE approval in follicular lymphoma
New ‘chemotherapy-free’ treatment for patients with limited options
FDA begins speedy review of BMS’ CAR-T liso-cel
Agency sets target action date of 17 August for final decision
Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls
BMS share price up by 3% on the back of results
Gilead owes BMS millions after losing Yescarta patent infringement trial
Jury found Gilead's CAR-T infringed on exclusive patent
BMS’ oral maintenance therapy boosts survival in AML patients
Drug improved survival by almost ten months
Armed with new data, BMS plans filings for Celgene CAR-T liso-cel
Achieved a 53% complete response rate in study participants
Amgen raises forecasts after closing $13.4bn Otezla deal
Scope to build product further with ongoing trials in additional indications